Glucocorticoid Receptor Suppresses Tumor Formation by Ensuring Accurate Chromosome Segregation During Mitosis
|
By LabMedica International staff writers Posted on 20 Apr 2015 |

Image: Electrophoretic data confirmed disruption of mitosis in cells lacking GR (Photo courtesy of the University of Manchester).
A team of British molecular biologists has defined the mechanism by which glucocorticoid receptor (GR) regulates the process of mitosis to prevent errors in cell division that could lead to tumor formation.
GR is a member of the nuclear receptor superfamily, which controls programs regulating cell proliferation, differentiation, and apoptosis. GR is expressed in almost every cell in the body and regulates genes controlling development, metabolism, and immune response. As the receptor gene is expressed in several forms, it has many different effects in various parts of the body. Unbound receptor resides in the cytosol of the cell. Binding of GR to glucocorticoids triggers its primary mechanism of action, which is the regulation of gene transcription. After the receptor is bound to glucocorticoid, the receptor-glucorticoid complex up-regulates the expression of anti-inflammatory proteins in the nucleus or represses the expression of pro-inflammatory proteins in the cytosol (by preventing the translocation of other transcription factors from the cytosol into the nucleus).
Investigators at the University of Manchester (United Kingdom) identified an additional role for GR related to regulation of cell division. They discovered that specifically modified GR species accumulated at the mitotic spindle during mitosis in a distribution that overlapped with enzymes of the Aurora kinase family. They found that Aurora A was required to mediate mitosis-driven GR phosphorylation, but not recruitment of GR to the spindle. GR was necessary for mitotic progression, with increased time to complete mitosis, frequency of mitotic aberrations, and death in mitosis observed following GR knockdown. Complementation studies revealed an essential role for the GR ligand-binding domain, but no clear requirement for ligand binding in regulating chromosome segregation.
GR haploinsufficient mice (animals with only a single functional copy of the GR gene that did not produce enough of the gene product to bring about the wild-type condition) had an increased incidence of tumor formation, and these tumors were further depleted for GR, implying additional GR loss as a consequence of cell transformation. Reduced GR expression was identified in a panel of human liver, lung, prostate, colon, and breast cancers.
The unexpected role for the GR in promoting accurate chromosome segregation during mitosis marked GR as an authentic tumor suppressor gene. "Cancer is caused by cell division going wrong, but no one has previously looked at the role GR has to play in this process," said senior author Dr. David Ray, professor of human development at the University of Manchester. "It is now clear that it is vital."
The study was published in the April 6, 2015, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
University of Manchester
GR is a member of the nuclear receptor superfamily, which controls programs regulating cell proliferation, differentiation, and apoptosis. GR is expressed in almost every cell in the body and regulates genes controlling development, metabolism, and immune response. As the receptor gene is expressed in several forms, it has many different effects in various parts of the body. Unbound receptor resides in the cytosol of the cell. Binding of GR to glucocorticoids triggers its primary mechanism of action, which is the regulation of gene transcription. After the receptor is bound to glucocorticoid, the receptor-glucorticoid complex up-regulates the expression of anti-inflammatory proteins in the nucleus or represses the expression of pro-inflammatory proteins in the cytosol (by preventing the translocation of other transcription factors from the cytosol into the nucleus).
Investigators at the University of Manchester (United Kingdom) identified an additional role for GR related to regulation of cell division. They discovered that specifically modified GR species accumulated at the mitotic spindle during mitosis in a distribution that overlapped with enzymes of the Aurora kinase family. They found that Aurora A was required to mediate mitosis-driven GR phosphorylation, but not recruitment of GR to the spindle. GR was necessary for mitotic progression, with increased time to complete mitosis, frequency of mitotic aberrations, and death in mitosis observed following GR knockdown. Complementation studies revealed an essential role for the GR ligand-binding domain, but no clear requirement for ligand binding in regulating chromosome segregation.
GR haploinsufficient mice (animals with only a single functional copy of the GR gene that did not produce enough of the gene product to bring about the wild-type condition) had an increased incidence of tumor formation, and these tumors were further depleted for GR, implying additional GR loss as a consequence of cell transformation. Reduced GR expression was identified in a panel of human liver, lung, prostate, colon, and breast cancers.
The unexpected role for the GR in promoting accurate chromosome segregation during mitosis marked GR as an authentic tumor suppressor gene. "Cancer is caused by cell division going wrong, but no one has previously looked at the role GR has to play in this process," said senior author Dr. David Ray, professor of human development at the University of Manchester. "It is now clear that it is vital."
The study was published in the April 6, 2015, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
University of Manchester
Latest BioResearch News
- Inherited Genetic Differences Help Explain Variable CAR T-Cell Therapy Outcomes
- AI-Powered Genome Mapping Reveals New Layer of Alzheimer’s Disease Biology
- Genetic Variations Reveal Mechanisms Behind Sudden Cardiac Death Risk
- Immune Biomarkers Support Early Risk Stratification in Oral Precancer
- Global Genetic Map Identifies Regional Parkinson’s Variants to Support Diagnostics
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
- Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
Channels
Clinical Chemistry
view channel
Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
Alzheimer’s disease is often first suspected in primary care, yet definitive evaluation frequently depends on specialized imaging or cerebrospinal fluid testing. This creates a persistent gap between disease... Read more
Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
Pheochromocytomas and paragangliomas are rare tumors that form in or near the adrenal glands and cause overproduction of stress hormones. Plasma-free metanephrines are the recommended first-line test,... Read moreMolecular Diagnostics
view channel
AI-Powered Liquid Biopsy Detects Liver Cancer Across Diverse Populations
Liver cancer remains a leading cause of cancer mortality worldwide, with incidence rising alongside the growing burden of metabolic liver disease. Early detection can substantially improve outcomes, yet... Read more
Circular RNAs Enable Noninvasive Cancer Detection and Risk Assessment
Liquid biopsy promises earlier cancer detection and agile treatment monitoring, but robust biomarkers that are stable and disease‑specific remain a hurdle. Circular RNAs (circRNAs) are structurally resilient... Read moreHematology
view channel
Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
Tuberculosis continues to be a leading global infectious disease, and diagnosis still hinges on sputum samples that many patients cannot produce early in illness. Delays in confirming Mycobacterium tuberculosis... Read more
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read morePathology
view channel
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channelPartnership Brings Automated Pathology Archiving Solutions to U.S. Labs
Accurate retention and retrieval of pathology blocks and slides underpin timely, reliable cancer diagnoses, yet manual archiving remains labor-intensive and error-prone for many laboratories.... Read more







